Second Georgian opposition leader placed in pre-trial detention as crackdown widens
TBILISI (Reuters) -A Georgian court on Friday placed Nika Melia, a leader of the country's main opposition party, in pre-trial detention, amid a widening crackdown against a pro-Western opposition that has staged months of anti-government protests.
Melia, a top leader of the Coalition for Change opposition bloc, was detained on Thursday for refusing to appear at a parliamentary inquiry into alleged crimes committed under jailed former President Mikheil Saakashvili between 2004 and 2012.
The length of the detention was not immediately clear.
Last week, a judge placed another leader of the Coalition for Change, Zurab Japaridze, in pre-trial detention for refusing to appear before the inquiry.
Friday's hearing was disorderly, with Melia sentenced after being removed from the courtroom for throwing water at the judge from the dock.
Previously one of the most pro-Western and democratic of the Soviet Union's successor states, Georgia under the leadership of the Georgian Dream party is accused by the ruling bloc's critics of moving in an authoritarian and pro-Russian direction.
Georgian Dream says it still wants the country to eventually join the European Union but wants to preserve what it calls Georgia's traditional values and also to avoid conflict with Russia, its giant neighbour and former imperial ruler.
Separately on Friday, another judge jailed a 19-year-old student activist for 12 days for insulting a Georgian Dream lawmaker she had called a "Russian slave" in a cafe this month.
Georgian Dream, after winning an election last November that the opposition says was rigged, said it would halt talks on joining the EU till 2028. EU membership has wide support among Georgians and the goal has been enshrined in the constitution.
The ruling party's decision to suspend the talks sparked mass street protests, prompting a violent crackdown and large-scale arrests by security forces.
Georgian Dream is dominated by billionaire ex-prime minister Bidzina Ivanishvili, who is widely seen as Georgia's de facto leader.
In December, the United States sanctioned Ivanishvili for what it said were actions aimed at dismantling Georgian democracy for the benefit of Russia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
US-EU trade deal impacts on pharma industry more 'manageable' than expected
A 15% import tariff on pharmaceutical goods from the European Union to the US is going to have a lesser impact on the pharmaceutical industry than Wall Street feared. Big pharmaceutical stocks like Pfizer (PFE), Eli Lilly (LLY), and Johnson & Johnson (JNJ) rose slightly, by about 1%, in trading Thursday after the trade deal was announced, putting to rest concerns of tariffs threatened as high as 200% previously by President Trump. "The two regions have established a 15% tariff cap on imported drugs from EU to the US. This is being viewed by most as both manageable and below the 20%+ rate many expected," wrote Mizuho's healthcare expert Jared Holz in a note to clients Thursday. The deal outlined by the US and EU has multiple parts that impact the pharmaceutical industry, with some clarity still needed. The first is levying either the 15% tariff or the Most Favored Nation (MFN) pricing, whichever is higher, on pharma drugs manufactured in the EU. This puts more emphasis on President Trump's efforts to equalize US drug costs to the lower prices seen in the EU and other developed nations and also impacts a smaller portion of products, as pharma executives have emphasized that most of the branded drugs sold in the US are made in the US. But questions remain on whether the finalize products, or some components, will be taxed. "The United States commits to apply the higher of either the US MFN tariff rate or a tariff rate of 15 percent, comprised of the MFN tariff and a reciprocal tariff, on originating goods of the European Union," according to the White House statement. The second part of the deal is that, as of Sept. 1, the US will enforce MFN pricing on generics and "chemical precursors." The latter refers to active pharmaceutical ingredients, which are the key chemical compounds in any drug. They are cheaper to mass-produce overseas, largely in Asia or Ireland. Experts say that prices for generics, which account for a majority of prescriptions filled in the US, are already low. "The administration is, for the time being, focusing Most Favored Nations pricing on generic products — hoping to peg US prices to that of other countries. Given the already lower cost of generic medicines and net price paid domestically, see the financial ramifications here as more limited than not. Have to look deeper at what precise drugs will be subject to this regulation but for now, not a strategy we see as stifling the industry/major players," Mizuho's Holz said. Its why big generics players, like Teva (TEVA), saw their stocks also rise on the news — up more than 4% Thursday. UBS analyst Ashwani Verma called the trade deal a positive for drugmakers, in a note to clients Thursday. The deal also left wiggle room for additional items: "The United States and the European Union agree to consider other sectors and products that are important for their economies and value chains for inclusion in the list of products for which only the MFN tariffs would apply," according to the White House statement. J.P. Morgan analyst Chris Schott told clients Thursday that clarity on details — including which components are chosen and how the tariffs are levied — as well as the pending results of an investigation by the US Department of Commerce Bureau of Industry and Security, will determine the final impact. In addition, Schott noted that many companies have already stocked up on products in advance of the expected tariff deal, and have inventory through mid-2026. "In the near-term, we see inventory stocking as largely limiting the impact of tariffs through mid-to-late 2026 or longer in some cases," Schott said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices
The Hill
10 minutes ago
- The Hill
Marjorie Taylor Greene, Megyn Kelly reveal why Israel is losing MAGA support
There are few women more important in the conservative media ecosystem than Megyn Kelly. The former Fox News host has her own podcast empire, and is among the most influential pro-Trump voices in independent media. Though initially combative with Donald Trump while previously serving as a host at Fox, Kelly has become an ideologically reliable enforcer and promoter of pro-Trump views, particular on cultural issues. On foreign policy, she has been an ardent defender of Israel and the U.S.'s special relationship with that country. And so it really means something when even Megyn Kelly is sounding less than enthusiastic about what Israel is doing in Gaza, about the level of financial support the U.S. is supplying to Israel, and the amount of influence the Israeli lobby exerts on the U.S. government. On her show this week, she invited on Rep. Marjorie Taylor Greene (R-Ga.) to discuss pro-Israel group AIPAC, and the sway it holds over other members of Congress. Like Kelly, MTG's MAGA credentials are unimpeachable. She is one of Trump' most reliable backers, and she believes in America First. But MTG is questioning whether reflexively supporting everything the Israeli government does is actually in America's best interests. She also resents the level of influence that AIPAC seems to exercise over her colleagues. Here is MTG explaining it to Kelly: 'Israel is the only country I know of that has some sort of incredible influence and control over nearly every single one of my colleagues. … I don't know how to explain it.' Elsewhere in the interview, Kelly does plenty of throat clearing. She says she has always supported Israel's right to defend itself, and still does. She would never ever side with a terrorist group. She's unwavering in that regard. But she knows that the ground is shifting. 'There's a contingent of people who are worried that they're 'losing me,' and I've said, you're not losing — I'm not on Hamas's side, but it's been a while now that this is going on, and we're getting more involved with the Iranian bombing and so on. My own feelings, I'm looking at Israel in a different way right now than I was on 10-8, that's for sure — of '23. And I can feel the pressure being slightly ratcheted up.' Megyn Kelly is not alone. The fact is that many, many, many people in the MAGA movement are becoming more suspicious of the Israeli government. That does not mean they are anti-Israel, and it certainly doesn't mean they're anti-Semitic. What it means is that Israel has a slow-rolling PR crisis on its hands. For decades, Israel has enjoyed unqualified support from Republicans and Democrats, and in exchange, the president of the United States was able to exercise some power over the Israeli government's actions in the Middle East. Presidents from Reagan to Bush to Clinton to Obama got to say, OK, enough is enough, we aren't getting dragged into World War III. But under the Biden administration that changed, as President Biden basically let Israeli Prime Minister Benjamin Netanyahu do whatever he wanted in Gaza as a result of October 7. Even as that ultimately meant the deaths of tens of thousands of innocent people, the utter destruction of Gaza, and the starvation of women and children. Israel's backers are now forced to present deeply uncomfortable arguments about how, well, such and such child is not really, starving, they were already very sick. These are not winning arguments, and MAGA is noticing. I've certainly noticed it — and I've been defending Israel's right to defeat the terrorist group Hamas for years. I've been uncompromising on this. But like Megyn Kelly, and like Marjorie Taylor Greene, I cannot defend an unending campaign that kills tens of thousands of children. I can't defend a foreign lobbying group sidestepping requirements that every other foreign government has to follow, like signing up under FARA. And I've never defended the aid money we send to Israel: Israel is a rich country with a lower debt-to-GDP ratio than the U.S. Let them buy our weapons with their own money. Which brings me to my last point. There are certainly elements of MAGA that want to back aid and support to Israel no matter what. I retweeted the MTG/Kelly interview on X, and Laura Loomer replied to me: 'MTG doesn't speak for MAGA.' True, she doesn't speak for everyone. But young, online, right-leaning MAGA folks are resentful of how much money we send to Israel. If Israel wants to restore its good standing with the America First crowd, they don't necessarily have to compromise their policies, but they should consider ending their reliance on our aid.
The Hill
10 minutes ago
- The Hill
Witkoff calls Trump the ‘Michael Jordan' of dealmaking amid Russia-Ukraine talks
U.S. special envoy Steve Witkoff on Wednesday recounted the Alaska summit last week with Russian President Vladimir Putin, calling President Trump the 'Michael Jordan' of dealmaking. In a radio interview on the 'Cats & Cosby Show,' Witkoff described to hosts John Catsimatidis and Rita Cosby what he and Secretary of State Marco Rubio witnessed behind closed doors ahead of Trump's high-stakes meeting with the Kremlin's leader. 'When the doors closed, John and Rita, in Alaska, I and Marco got to witness the great master, master dealmaker-in-chief, Donald J. Trump,' Witkoff said. 'And it was quite extraordinary to watch.' 'We've all grown up in New York and we've all done deals, but President Trump is, you know, he's the Michael Jordan of this business. In fact, he's the Michael Jordan, Tiger Woods and Albert Einstein all put together,' Witkoff continued. Witkoff has held several sessions with Putin in recent months as the Trump administration has sought to broker a diplomatic end to the war between Russia and Ukraine. While his own talks with Putin were constructive, Witkoff said in the interview that Trump has 'got this uncanny ability to get to the right place' and was able to make significantly more progress in his meeting with the Russian leader last Friday. 'I think he felt that we made a lot of progress in a one-on-one with Putin,' Witkoff said. 'What we were able to determine, and I hope it holds, that the Russians are prepared to be accommodating — more accommodating than we had seen in five or six sessions that I had with him, with President Putin.' 'They were positive and constructive sessions,' Witkoff said about his own meetings with Putin, 'but the president was able to extract more concessions in that Alaska summit — significantly more — with regard to the regions, with regard to the territories, with regard to security protocols.' 'A lot of things were given or were offered up as a compromise, as an accommodation, by President Putin. That is a really big deal because… that's the deal making business,' Witkoff said, 'Narrowing the issues between the parties. And that's what happened, by the way, in Alaska, we narrowed the issues and the divide.' Trump emerged from the meeting Friday with no concrete wins but touted the progress made behind closed doors. He then met with Ukrainian President Volodymyr Zelensky and other European leaders at the White House on Monday to discuss next steps. Trump has said the next step is for Zelensky and Putin to meet for a bilateral meeting, after which Trump said he would join for a trilateral meeting. Witkoff said during the interview he expects a trilateral meeting, if it takes place, would produce the most progress. 'The next move is going to be very telling as to whether Zelensky and Putin meet together. And I think ultimately, if that happens, if that meeting happens — and I believe it will, I'm certainly hopeful it will — that will, in my view, potentially lead to a trilateral between the three, and there, I think you'd see a lot more progress,' Witkoff said.
